Abstract
Purpose
To evaluate acute and late skin/subcutaneous toxicities and radiation-induced lung fibrosis (RILF) in patients treated with adjuvant radiotherapy (RT) for synchronous bilateral breast cancers (SBBC), after conservative surgery.
Methods/patients
Twenty-five patients were treated with volumetric-modulated arc therapy (VMAT/RapidArc®) on both breasts, and checked clinically for detecting RT toxicities during and after treatment. A high-resolution computed tomography (HRCT) was performed, for detecting RILF during follow-up.
Results
We registered acute Grade-1 skin toxicity in 18 patients (72%), while six patients (24%) experienced Grade-2 toxicity. No breath symptoms were reported during and after RT. Late Grade-1 subcutaneous toxicity and late Grade-2 skin toxicity were registered in four patients (16%) and one patient (4%), respectively, at a mean follow-up of 36 months. Grade-1 RILF was detected in six patients (30%). The median volume of fibrosis area was 6.5 cc (range 1.3–21.5 cc). The partial volumes receiving a specified dose (V20, V30, V40, and V50) in patients who developed lung fibrosis were significantly bigger than who did not (p < 0.01). We showed that the mean volume of the tumour boost of patients who developed fibrosis (77.7 cc) was not significantly different from the other patients (90.8 cc) (p = 0.5).
Conclusion
The clinical impact of this technique is favourable, and this is the first clinical study showing RILF by HRCT in a setting of SBBC. Further study with larger accrual is mandatory.
Similar content being viewed by others
References
Padmanabhan N, Subramanyan A, Radhakrishna S. Synchronous bilateral breast cancers. J Clin Diagn Res. 2015;9:XC05–8.
Kheirelseid EA, Jumustafa H, Miller N, Curran C, Sweeney K, Malone C, et al. Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat. 2011;126:131–40.
Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol. 2002;28:388–91.
Schwentner L, Wolters R, Wischnewsky M, Kreienberg R, Wockel A. Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast. 2012;21:171–7.
Bantema-Joppe EJ, Schilstra C, de Bock G, Dolsma WV, Busz DM, Langendijk JA, et al. Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months’ follow-up. Int J Radiation Oncol Biol Phys. 2012;83:471–7.
Lee T-F, Chao P-J, Chang L, Ting H-M, Huang Y-J. Developing multivariable normal tissue complication probability model to predict the incidence of symptomatic radiation pneumonitis among breast cancer patients. PLoS ONE. 2015;10:e0131736.
Nicolini G, Clivio A, Fogliata A, Vanetti E, Cozzi L. Simultaneous integrated boost radiotherapy for bilateral breast: a treatment planning and dosimetric comparison for volumetric modulated arc and fixed field intensity modulated therapy. Radiat Oncol. 2009;4:27.
Seppälä J, Heikkilä J, Myllyoja K, Koskela K. Volumetric modulated arc therapy for synchronous bilateral whole breast irradiation: a case study. Rep Pract Oncol Radiother. 2015;20:398–402.
Kim SJ, Lee MJ, Youn SM. Radiation therapy of synchronous bilateral breast carcinoma (SBBC) using multiple techniques. Med Dosim. 2017;43:55.
Oh YT, Noh OK, Jang H, Chun M, Park KJ, Park KJ, Kim MH, Park HJ. The features of radiation induced lung fibrosis related with dosimetric parameters. Radiother Oncol. 2012;102:343–6.
Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Pract Radiat Oncol. 2016;6:287–95.
Cutuli B, Wiezzane N, Palumbo I, Barbieri P, Guenzi M, Huscher A, et al. Breast-conserving treatment for ductal carcinoma in situ: impact of boost and tamoxifen on local recurrences. Cancer Radiother. 2016;20:292–8.
Radiation Therapy Oncology Group (RTOG) Breast cancer atlas for radiation therapy planning: consensus definitions. http://rtog.org/LinkClick.aspx?fileticket=vzJFhPaBipE%3d&tabid=236. Accessed 05 Nov 2018.
Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–8.
Taylor CW, McGale P, Povall JM, Thomas E, Kumar S, Dodwell D, et al. Estimating cardiac exposure from breast cancer radiotherapy in clinical practice. Int J Radiat Oncol Biol Phys. 2009;73:1061–8.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.
Kubo A, Osaki K, Kawanaka T, Furutani S, Ikushima H, Nishitani H. Risk factors for radiation pneumonitis caused by whole breast irradiation following breast conserving surgery. J Med Invest. 2009;56:99–110.
Blom Goldman U, Wennberg B, Svane G, Bylund H, Lind P. Reduction of radiation pneumonitis by V20-constraints in breast cancer. Blom Radiat Oncol. 2010;5:99.
Ramella S, Trodella L, Mineo TC, Pompeo E, Stimato G, Gaudino D, et al. Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA–B NSCLC treated with combined-modality therapy. Int J Radiat Oncol Biol Phys. 2010;76:110–5.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.
Anonymous (2009) Cancer therapy evaluation program. Common terminology criteria for adverse events, version 4.02, DCTD, NCI, DHHS.
Fiorentino A, Mazzola R, Naccarato S, Giaj-Levra N, Fersino S, Sicignano G, et al. Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost. Radiol Med. 2017;122(6):464–71.
Kaidar-Person O, Kostich M, Zagar TM, Jones E, Gupta G, Mavroidis P, et al. Helical tomotherapy for bilateral breast cancer: clinical experience. Breast. 2016;28:79–83.
Fragkandrea I, Kouloulias V, Mavridis P, Zettos A, Betsou B, Georgolopoulou P, et al. Radiation induced pneumonitis following whole breast radiotherapy treatment in early breast cancer patients treated with breast conserving surgery: a single institution study. Hippokratia. 2013;7:233–8.
Aznar MC, Duane FK, Darby SC, Wang Z, Taylor CW. Exposure of the lungs in breast cancer radiotherapy: a systematic review of lung doses. Radiother Oncol. 2018;126:148–54.
Gaudino D, Cima S, Frapolli M, Daniele D, Muoio B, Pesce GA, et al. Volumetric modulated arc therapy applied to synchronous bilateral breast cancer radiotherapy: dosimetric study on deep inspiration breath hold versus free breathing set up. Biomed Phys Eng Express. 2018;4:045007.
Wen G, Tan YT, Lan XW, He ZC, Huang JH, Shiet JT, et al. New clinical features and dosimetric predictor identification for symptomatic radiation pneumonitis after tangential irradiation in breast cancer patients. J Cancer. 2017;8:3795–802.
Wennberg B, Gagliardi G, Sundbom L, Svane G, Lind P. Early response of lung in breast cancer irradiation: radiologic density changes measured by CT and symptomatic radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2002;52:1196–206.
Wadasadawala T, Jain S, Paul S, Phurailatpam R, Joshi K, Popat P, et al. First clinical report of helical tomotherapy with simultaneous integrated boost for synchronous bilateral breast cancer. Br J Radiol. 2017;90(1077):20170152.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Valli, M., Cima, S., Gaudino, D. et al. Skin and lung toxicity in synchronous bilateral breast cancer treated with volumetric-modulated arc radiotherapy: a mono-institutional experience. Clin Transl Oncol 21, 1492–1498 (2019). https://doi.org/10.1007/s12094-019-02077-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-019-02077-z